Late Breaking News
Follow Us
2012 Compendium
Content Archive
New Therapies, Programs Affect Hepatitis C Treatment within VA
Chronic infection with hepatitis C virus (HCV) is the most common bloodborne infection in the United States, affecting more than three million Americans. HCV-infected patients are much more likely than the general U.S. population to develop life-threatening complications, such as cirrhosis, end-stage liver disease or hepatocellular carcinoma (HCC). Although antiviral treatment can cure HCV infection, these therapies have historically had low efficacy rates and significant toxicities.
Study: Exercise Reduces Prostate Cancer Risk in Caucasians, But Not African-Americans
Researchers Trying to Understand Why
DURHAM, NC - Researchers are grappling with the results of a new study that shows an association between increased exercise and reduced risk of prostate cancer in white men but not black men.
TRICARE Faces Challenges in Getting Males to Complete Three-Shot HPV Vaccine Series
Immunization Now Covered for Men Up to Age 27
FALLS CHURCH, VA - In the year since TRICARE added coverage for the human papillomavirus (HPV) vaccine in all males up to age 27, the challenge has been both educating military personnel and their families about the need for the shots and assuring that the recommended three doses are received.
The PhARMD Program: Documenting Pharmacist Impact on VA Patient Outcomes
WEST PALM BEACH, FL - How much of a role are clinical pharmacists playing in patient care at VA?
Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies
WAYNE, NJ - Tthe U.S. Food and Drug Administration (FDA) has approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate, according to Bayer HealthCare and Onyx Pharmaceuticals, Inc.
Ofirmev Injection Available on VA Formulary For Relief of Mild/Moderate Pain
SAN DIEGO - Cadence Pharmaceuticals, Inc. announced that Ofirmev (acetaminophen) injection has been made available on the VA National Formulary (VANF) and must be available for prescription at all VA facilities.
Kadcyla Approved for Treatment of HER2-positive Metastatic Breast Cancers
SAN FRANCISCO - The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
Retired Air Force Urologist, General Officer Urges Doctors to Take Command
TEMPLE, TX - Retired Brig. Gen. James T. Turlington, MD, may no longer be an active duty general officer in the Air Force, but he’s still practicing medicine — and still making a difference.
Lawmakers Seek Continued TBI Funding to Benefit Veterans, Civilians
WASHINGTON - Lawmakers are calling for the reauthorization of legislation to help traumatic brain injury (TBI) patients and their families access rehabilitation, long-term care and community support.
Controversy Continues Over Abridged Plans to Develop Joint VA, DoD EHR
WASHINGTON - The new plan to develop a joint DoD, VA iEHR is a "lower risk, lower cost path," agency officials told a congressional committee.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Education
Join Our E-Mail List


